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eart failure (HF) has become the major epidemic of the
ew millennium, and use of the left ventricular (LV) assist
evice (LVAD) for mechanical support in end-stage HF is
ncreasing. Introduced as an alternative to heart transplan-
ation, LVADs were approved by the Food and Drug
dministration a decade ago to provide a bridge to trans-
lantation in the moribund end-stage HF patient waiting
or a donor heart. However, LVAD is now becoming a
ife-saving treatment option for patients with severe HF
efractory to optimal medical therapy that includes renin-
ngiotensin-aldosterone system (RAAS) inhibitors, beta-
drenergic blockers, inotropes, and diuretics. The
EMATCH (Randomized Evaluation of Mechanical As-
istance for the treatment of Congestive Heart Failure) trial
See page 1166
n 129 patients established the efficacy of LVAD as a new
ong-term myocardial replacement therapy for end-stage
F (1). Compared to medical therapy, LVAD support
oubled survival at 1 year (from 25% to 52%) and tripled it
t 2 years (from 8% to 23%) and improved functional status
nd quality of life, but there were adverse events (1).
nterestingly, in the 91 inotrope-dependent REMATCH
atients, LVAD doubled survival at 1 year (from 24% to
9%) and 2 years (from 11% to 28%) (2). These findings
roadened the use of LVADs to include inotrope-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Division of Cardiology, Department of Medicine, and the ‡Cardiovas-
ular Research Group, University of Alberta, Edmonton, Canada. This work wasg
upported in part by grants from the Canadian Institutes of Health and Canadian
eart and Stroke Foundation, Ottawa, Ontario (to Dr. Jugdutt).ependent and transplant-ineligible patients. New genera-
ions of compact, implantable LVADs are being considered
s alternative therapy for severe chronic and refractory HF.
lthough LVAD support as a bridge to recovery may be
ossible in some patients, LV recovery and successful
VAD explantation is the exception rather than the rule.
raditional concepts of matrix modulation and adverse
emodeling in HF. On the basis of collective knowledge
3), 4 points merit emphasis. First, cardiac remodeling is a
ey determinant of outcome in HF, and remodeling of the
xtracellular collagen matrix (ECCM) plays a critical role in
dverse LV remodeling and dysfunction in chronic HF.
Second, end-stage HF is associated with adverse cardiac
emodeling involving LV dilation, eccentric hypertrophy,
hape change from elliptical to spherical, significant inter-
titial fibrosis and increase in ECCM, and LV systolic and
iastolic dysfunction. Notably, altered fibroblast function,
ith increased production of ECCM and other proteins,
uch as matrix metalloproteinases (MMPs) that degrade
CCM, and impaired fibroblast/cardiomyocyte interaction
ontribute to LV structural remodeling and dysfunction.
he main fibrillar collagens of the ECCM are types I and
II, and the type I/III ratio is increased in dilated cardio-
yopathy. Increased collagen type I and cross-linking
ssociated with fibrosis cause LV stiffening and impaired
ontraction and relaxation, whereas newly synthesized col-
agen type III, being immature, contributes to LV dilation.
Third, up-regulation of the RAAS and other neurohu-
oral systems plays an important role in the modulation of
yocardial and ECCM remodeling and progression to
nd-stage HF. Circulating or tissue angiotensin II (AngII),
ldosterone, norepinephrine, endothelin, vasopressin, and
ther cytokines all contribute to adverse LV remodeling and
ysfunction. However, AngII and transforming growth
actor (TGF)-beta1 are among the important regulators of
ardiac fibrosis.
Fourth, an imbalance between MMPs and tissue inhibitors
f MMPs (TIMPs) drives adverse ECCM and LV remodel-
ng. In HF, increased MMP-1, -2, and -9 and decreased
IMP-1, -3, and -4 have been implicated in adverse ECCM
nd LV remodeling, and the MMP-1/TIMP-1 or MMP-9/
IMP-3 ratio modulate ECCM turnover.
V unloading, ECCM, and function. The traditional
oncept is that increased load leads to increased wall stress
nd stretch, increased AngII, hypertrophy, and increased
ollagen (content, type I, and cross-linking) and stiffness,
esulting in diastolic and systolic dysfunction. Conversely,
ecreased load would be expected to decrease AngII, hy-
ertrophy, and collagen and stiffness and improve diastolic
nd systolic function.
However, there are exceptions. Cumulative evidence
ndicates that AngII stimulates different signaling pathways
n cardiomyocytes and fibroblasts (4). Cardiomyocyte hy-
ertrophy is primarily load-dependent, whereas fibroblast
rowth is primarily load-independent, and RAAS activation
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Editorial Comment March 20, 2007:1175–7s the major stimulus for fibrosis rather than load. Not
urprisingly, RAAS inhibition with angiotensin-converting
nzyme (ACE) inhibitors (ACE-Is), AngII type 1 receptor
ntagonists, or aldosterone antagonists inhibits myocardial
brosis and decreases ECCM.
Consistent with the “decrease load¡ decrease hypertro-
hy” paradigm, mechanical LV unloading with the LVAD
ormalizes the diastolic properties of hearts with end-stage
F and results in a reversal of adverse remodeling. This is
videnced by an improved LV passive end-diastolic
ressure-volume relation, regression of LV hypertrophy,
nd a trend toward improved cardiomyocyte function,
alcium cycling, and gene expression.
Despite improved LV size and myocardial mechanics,
nergetics, morphology, and cell signaling during LVAD
se, ECCM remodeling is not reversed. This apparent
isconnect or paradox is not surprising if one considers that
broblast function is mostly load-independent. In fact,
lotz et al. (5) showed that LVAD use in 16 patients
aradoxically increased LV collagen cross-linking, collagen
ype I/III ratio and stiffness, normalized tissue MMP-1/
IMP-1 ratio (i.e., decreased ECCM degradation), and
ncreased tissue AngII (i.e., stimulating ECCM synthesis).
ecently, Bruggink et al. (6) showed that reverse remodel-
ng of the ECCM during LVAD use is biphasic, with an
ncrease in collagen volume fraction over the first 200 days,
decline between 200 and 400 days, and normalization after
00 days, and these changes paralleled those in type I and
ype III collagen turnover.
Another apparent paradox with LVAD use is that suffi-
ient recovery to allow explantation is rarely achieved.
hether this is due to persistent adverse ECCM remodel-
ng and can be reversed with combination therapy is not
nown.
CE inhibition and the ECCM. Angiotensin-converting
nzyme inhibitors are widely used for chronic therapy of
F. Collective evidence indicates that ACE-Is effectively
ecrease ECCM and fibrosis by at least 5 mechanisms
3,7,8) (Table 1). However, partial escape of the RAAS
uring ACE-I therapy leads to normalization of AngII
evels, partly owing to AngII production via alternative
athways, thereby providing rationale for adding AngII type
receptor antagonists and aldosterone antagonists.
ive Mechanisms for Antifibrotic Effects of ACE-Is
Table 1 Five Mechanisms for Antifibrotic Effects of ACE-Is
ACE inhibition: decrease AngII formation (3,5)
Kininase II inhibition: increase bradykinin (3,5)
Alter MMP/TIMP balance: decrease MMP activity (3,5)
Inhibition of Ang-(1-7) metabolism: increase Ang-(1-7) and increase Ang I (8)
Inhibition of Ac-SDKP hydrolysis,2 fibroblast proliferation,2 TGF- (7)
eference number is provided in parentheses at the end of each entry.
ACE-Is  angiotensin-converting enzyme inhibitors; Ac-SDKP  N-acetyl-seryl-aspartyl-lysyl-s
roline; Ang  angiotensin; MMP  matrix metalloproteinase; TGF  transforming growth factor;
IMP  tissue inhibitor of MMP.V unloading and function: apparent paradoxes during
VAD. In this issue of the Journal, Klotz et al. (9) report
hat ACE inhibition during LVAD use decreased tissue
ngII, total and cross-linked collagen and LV stiffness, and
ormalized the MMP-1/TIMP-1 ratio in 7 end-stage HF
atients relative to 15 control patients. In the right ventricle
RV), ACE-Is decreased AngII and normalized the
MP-1/TIMP-1 ratio but not collagen, mass, or size. The
CE-Is shifted the LV ex vivo end-diastolic pressure-
olume relation to the left and decreased LV mass but did
ot improve myocardial force generation in isolated trabec-
lae. Although that study was small, retrospective, and
bservational, the finding that ACE-I therapy prevents the
ncrease in LV tissue AngII, and that adverse ECCM and
V remodeling during prolonged LVAD use is provocative,
as potential for clinical application and deserves confirma-
ion in a larger, adequately powered trial. The findings with
CE inhibition in the RV are also provocative. The
uggestion that both unloading and ACE inhibition are
eeded to decrease RV collagen and mass (and presumably
o normalize the MMP-1/TIMP-1 ratio) in these patients
s important and requires verification in other settings.
Several additional features in the study by Klotz et al. (9)
eserve comment. First, the finding that increased tissue
ngII is associated with increased cross-linked collagen and
yocardial stiffness is consistent with the traditional con-
ept. However, that this should occur during prolonged
echanical unloading with LVAD over a mean of 96 days
s intriguing and contrary to the traditional concept. Klotz
t al. (9) explains this paradox by suggesting that concom-
tant decrease in load and tissue AngII is essential for
reventing fibrosis. This explanation needs to be reconciled
ith the fact that prolonged ACE inhibition may increase
irculating and tissue AngII levels in patients with HF.
oreover, ACE-I–induced increase in bradykinin and nor-
alization of the MMP-1/TIMP-1 ratio (Table 1) may
ontribute to reverse ECCM remodeling.
Second, although Bruggink et al. (6) also reported adverse
CCM remodeling during LVAD use, they found that
VAD has a biphasic effect on collagen volume, with an
ncrease over the first 200 days and a decrease followed by
ormalization thereafter. They also noted that ACE-Is did
ot affect collagen volume after LVAD. This discordance
uggests that larger groups of patients need to be studied for
onger periods.
Third, 2 important limitations of the study by Klotz et al.
9) are that they did not measure changes in: 1) the
brogenic cytokine TGF-beta1; and 2) in vivo systolic
unction or diastolic function or LV remodeling by
-dimensional (2D) echocardiography and tissue Doppler
maging or other modalities.
uture direction. Targeting the ECCM with combination
herapy during LVAD may improve LV functional recovery
nd outcome in patients with end-stage HF. The concept
hat adjunctive therapies might improve outcome and allow
uccessful weaning from LVADs deserves to be tested in a
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March 20, 2007:1175–7 Editorial Commentarge, adequately powered, multicenter, randomized clinical
rial that includes serial measurements of systolic and
iastolic function by 2D echocardiography/tissue Doppler
maging. Some potentially successful combination strategies
Figure 1 Potential Therapeutic Adjuncts for
LVAD Support in End-Stage Heart Failure
AA  angiotensin-aldosterone; ACE-Is  angiotensin-converting enzyme inhibi-
tors; AngII  angiotensin II; ARB  angiotensin receptor blocker; ECCM 
extracellular collagen matrix; HGF  hepatocyte growth factor; IGF  insulin-
like growth factor; LVAD  left ventricular assist device; LV  left ventricular;
MMP  matrix metalloproteinase; RAAS  renin-angiotensin-aldosterone sys-
tem; TIMP  tissue inhibitor of MMP; VEGF  vascular endothelial growth
factor.hat may be tested for maximizing reverse ECCM and LVemodeling and optimizing functional recovery during
VAD support are shown in Figure 1. These may well
ncrease the likelihood of successful weaning of some
atients from LVADs, as demonstrated with use of the
eta2-adrenergic agonist clenbuterol (10). It may also be-
ome possible to use molecular markers for identifying
esponders to the adjunctive pharmacotherapies.
eprint requests and correspondence: Dr. Bodh I. Jugdutt, 2C2
alter MacKenzie Health Sciences Centre, Division of Cardiol-
gy, University of Alberta, Edmonton, Alberta T6G 2R7, Canada.
-mail: bjugdutt@ualberta.ca.
EFERENCES
1. Rose EA, Gelijns AC, Moskowitz AJ, et al., Randomized Evaluation
of Mechanical Assistance for the Treatment of Congestive Heart
Failure (REMATCH) Study Group. Long-term mechanical left
ventricular assistance for end-stage heart failure. N Engl J Med
2001;345:1435–43.
2. Stevenson LW, Miller LW, Desvigne-Nickens P, et al., REMATCH
Investigators. Left ventricular assist device as destination for patients
undergoing intravenous inotropic therapy: a subset analysis from
REMATCH (Randomized Evaluation of Mechanical Assistance in
Treatment of Chronic Heart Failure). Circulation 2004;110:975–81.
3. Jugdutt BI. Remodeling of the myocardium and potential targets in
the collagen degradation and synthesis pathways. Curr Drug Targets
Cardiovasc Haematol Disord 2003;3:1–30.
4. Manabe I, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis:
involvement in cardiac hypertrophy. Circ Res 2002;91:1103–13.
5. Klotz S, Foronjy RF, Dickstein ML, et al. Mechanical unloading
during left ventricular assist device support increases left ventricular
collagen cross-linking and myocardial stiffness. Circulation 2005;112:
364–74.
6. Bruggink AH, van Oosterhout MF, de Jonge N, et al. Reverse
remodeling of the myocardial extracellular matrix after prolonged left
ventricular assist device support follows a biphasic pattern. J Heart
Lung Transplant 2006;25:1091–8.
7. Peng H, Carretero OA, Vuljaj N, et al. Angiotensin-converting
enzyme inhibitors: a new mechanism of action. Circulation 2005;112:
2436–45.
8. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and
functional roles of angiotensin-converting enzyme 2 and angiotensin-
(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ
Physiol 2005;289:H2281–90.
9. Klotz S, Danser AHJ, Foronjy RF, et al. The impact of angiotensin-
converting-enzyme inhibitor therapy on the extracellular collagen
matrix during left ventricular assist device support in patients with
end-stage heart failure. J Am Coll Cardiol 2007;49:1166–74.
0. Hon JK, Yacoub MH. Bridge to recovery with the use of left
ventricular assist device and clenbuterol. Ann Thorac Surg 2003;75
Suppl:S36–41.
